Aimmune Therapeutics Inc., of Brisbane, Calif., appointed Daniel C. Adelman chief medical officer.

Atreca Inc., of Redwood City, Calif., appointed Lawrence Fong technical advisor.

Aviragen Therapeutics Inc., of Atlanta, appointed Jonas Niaura vice president, corporate development and strategy.

Citius Pharmaceuticals Inc., of Cranford, N.J., added Eugene Holuka to its board.

Heron Therapeutics Inc., of Redwood City, Calif., added Christian Waage to its board.

Johnson & Johnson, of New Brunswick, N.J., named Joseph Wolk vice president, investor relations, effective Aug. 1.

Kamada Ltd., of Ness Ziona, Israel, appointed Naveh Tov vice president, clinical development and medical director for pulmonary diseases.

Keryx Biopharmaceuticals Inc., of Boston, named Douglas Jermasek vice president, marketing and strategy.

Millendo Therapeutics Inc., of Ann Arbor, Mich., added James Hindman to its board and named Carol Gallagher board chairman.

Mirati Therapeutics Inc., of San Diego, appointed Rodney Lappe executive chairman; he will act as an advisor to the management team during a time of transition.

Momenta Pharmaceuticals Inc., of Cambridge, Mass., added Steven C. Gilman to its board.

Rockwell Medical Inc., of Wixom, Mich., added Robin L. Smith to its board.

Symic Biomedical Inc., of Emeryville, Calif., appointed Carolyn Bertozzi to its scientific advisory board.

Uniqure NV, of Amsterdam, the Netherlands, appointed Maria E. Cantor senior vice president, investor relations and communications. She will be based in Lexington, Mass.